Jounce Therapeutics Historical PE Ratio image   This JNCE PE ratio history page last updated 5/10/2023
Jounce Therapeutics Historical PE Ratio Chart
PeriodPriceGAAPAnnualizedPE
Q4 2022
3/10/2023
0.900.983.920.2
Q3 2022
11/10/2022
1.17-0.60-2.40NA
Q2 2022
8/4/2022
3.62-0.65-2.60NA
Q1 2022
5/5/2022
4.86-0.72-2.88NA
Q4 2021
3/2/2022
7.22-0.59-2.36NA
Q3 2021
11/4/2021
9.61-0.59-2.36NA
Q2 2021
8/5/2021
5.20-0.08-0.32NA
Q1 2021
5/4/2021
8.53-0.58-2.32NA
Q4 2020
2/25/2021
11.760.863.443.4
Q3 2020
11/6/2020
6.76-0.73-2.92NA
Q2 2020
8/7/2020
4.80-0.82-3.28NA
Q1 2020
5/6/2020
5.01-0.78-3.12NA
Q4 2019
2/27/2020
4.55-0.68-2.72NA
Q3 2019
11/7/2019
4.002.9011.600.3
Q2 2019
8/7/2019
4.04-0.21-0.84NA
Q1 2019
5/8/2019
5.57-0.38-1.52NA
Q4 2018
3/6/2019
4.39-0.06-0.24NA
Q3 2018
11/13/2018
4.40-0.23-0.92NA
Q2 2018
8/9/2018
7.72-0.14-0.56NA
Q1 2018
5/9/2018
16.64-0.40-1.60NA
Q4 2017
3/8/2018
26.08-0.29-1.16NA
Q3 2017
11/13/2017
14.81-0.13-0.52NA
Q2 2017
8/9/2017
11.47-0.11-0.44NA
Q1 2017
5/9/2017
24.17-0.02-0.08NA
Q4 2016
3/10/2017
22.280.050.20111.4
Jounce Therapeutics PE History Chart
PeriodPriceGAAPTTMPE
Q4 2022
3/10/2023
0.900.98-0.99NA
Q3 2022
11/10/2022
1.17-0.60-2.56NA
Q2 2022
8/4/2022
3.62-0.65-2.55NA
Q1 2022
5/5/2022
4.86-0.72-1.98NA
Q4 2021
3/2/2022
7.22-0.59-1.84NA
Q3 2021
11/4/2021
9.61-0.59-0.39NA
Q2 2021
8/5/2021
5.20-0.08-0.53NA
Q1 2021
5/4/2021
8.53-0.58-1.27NA
Q4 2020
2/25/2021
11.760.86-1.47NA
Q3 2020
11/6/2020
6.76-0.73-3.01NA
Q2 2020
8/7/2020
4.80-0.820.627.7
Q1 2020
5/6/2020
5.01-0.781.234.1
Q4 2019
2/27/2020
4.55-0.681.632.8
Q3 2019
11/7/2019
4.002.902.251.8
Q2 2019
8/7/2019
4.04-0.21-0.88NA
Q1 2019
5/8/2019
5.57-0.38-0.81NA
Q4 2018
3/6/2019
4.39-0.06-0.83NA
Q3 2018
11/13/2018
4.40-0.23-1.06NA
Q2 2018
8/9/2018
7.72-0.14-0.96NA
Q1 2018
5/9/2018
16.64-0.40-0.93NA
Q4 2017
3/8/2018
26.08-0.29-0.55NA
Q3 2017
11/13/2017
14.81-0.13-0.21NA
Q2 2017
8/9/2017
11.47-0.11NANA
Q1 2017
5/9/2017
24.17-0.02NANA
Q4 2016
3/10/2017
22.280.05NANA
Quotes delayed 20 minutes

Email EnvelopeFree JNCE Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
10 Most Oversold S&P 500 Stocks
10 Most Overbought S&P 500 Stocks
10 ETFs With Stocks Insiders Are Buying
10 ETFs With Most Upside To Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active S&P Call & Put Options
Jounce Therapeutics (JNCE) is categorized under the Healthcare sector; to help you further research PE history across stocks, below are some other companies in the same sector:

JNJ PE Ratio History
KALA PE Ratio History
KALV PE Ratio History
KDMN PE Ratio History
KDNY PE Ratio History
KEQU PE Ratio History
KIDS PE Ratio History
KIN PE Ratio History
KLDO PE Ratio History
KMPH PE Ratio History
How should the JNCE historical PE ratio be determined?
Realizing that PE stands for Price to Earnings ratio, we need two values to compute it: stock price and earnings per share. The stock price at any given date is a known historical value, but what about the earnings number to use?

✔️Accepted answer: There are a number of different approaches when it comes to calculating a historical PE ratio for a company like Jounce Therapeutics. We like to take our measurements on each of the past quarterly earnings reports. That only leaves the question of whether the earnings number at that quarterly report should be used on an annualized basis, or some other method. We approach this question using three different methods, on this JNCE Historical PE Ratio page.

What is the average historical PE for JNCE based on annualized quarterly earnings?
As we look back through earnings history, what is the resulting PE calculation if at each measurement period we use that quarter's earnings result annualized?

✔️Accepted answer: The JNCE historical PE ratio using the annualized quarterly earnings method works out to 28.8.

What is the average historical PE for JNCE based on trailing twelve month earnings?
As we look back through earnings history, what is the resulting PE calculation if at each measurement period we use the trailing twelve months combined earnings result in the calculation?

✔️Accepted answer: The JNCE historical PE ratio using the TTM earnings method works out to 4.1.

On this page we presented the Jounce Therapeutics Historical PE Ratio information for Jounce Therapeutics' stock. The average JNCE historical PE based on using the annualized quarterly earnings result at each measurement period (for the "E" in the PE calculation; and the closing price on earnings date as the "P") is 28.8. Meanwhile, using the trailing twelve month (TTM) quarterly earnings result as our method of calculation the "E" value at each measurement period, the average JNCE historical PE based on this TTM earnings result method is 4.1. Note: any PE calculations involving negative earnings were discarded as not meaningful.

Let's now compare this JNCE historical PE result, against the recent PE: when this page was posted on 5/4/2023, the most recent closing price for JNCE had been 1.88, and the most recent quarterly earnings result, annualized, was 3.92. Meanwhile, the most recent TTM earnings summed to 0.62. From these numbers, we calculate the recent JNCE PE on 5/4/2023 based on annualized quarterly EPS was 0.5. Based on JNCE's history, that recent PE is low relative to the historical average, with the recent PE 98.3% lower than the historical average PE across our data set for Jounce Therapeutics. Looking at the recent JNCE PE on 5/4/2023 based on TTM EPS, we calculate the ratio at 3.0. Based on JNCE's history, that recent PE is low relative to the historical average, with the recent PE 26.8% lower than the average PE across our Jounce Therapeutics data set with TTM EPS used in the calculation at each period.

For self directed investors doing their due diligence on JNCE or any other given stock, valuation analysis for JNCE can greatly benefit from studying the past earnings and resulting PE calculations. This exercise can help inform an analysis as to whether the past earnings trajectory and current versus historical PE ratios justify the current stock value.

That's why we bring you HistoricalPERatio.com to make it easy for investors to investigate Jounce Therapeutics PE history or the past PE information for any stock in our coverage universe. And in your continued research we hope you will be sure to check out the further links included for earnings surprises history (beat/miss data) as well as next earnings dates for JNCE. Thanks for visiting, and the next time you need to research JNCE Historical PE Ratio or the ratio for another stock, we hope you'll think of our site, as your go-to historical PE ratio research resource of choice.

Recommended: Institutional Holders of VCM, Funds Holding GLDD, Funds Holding SBEU.

 

Jounce Therapeutics Historical PE Ratio | www.HistoricalPERatio.com | Copyright © 2020 - 2023, All Rights Reserved

Nothing in HistoricalPERatio.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.
X
Wait! Don't leave yet.
Want to receive our latest research absolutely free?


Click the button below for your complimentary copy of Your Early Retirement Portfolio: Dividends Up to 7.8%—Every Month—Forever.

You'll discover the details on 4 stocks and funds that pay you massive dividends as high as 7.8%.